Common Side Effects Patients Report with Wegovy
Wegovy (semaglutide) causes gastrointestinal issues in most users. Nausea affects up to 44% of patients, vomiting 24%, diarrhea 30%, constipation 24%, and abdominal pain 20%. These often start early and decrease over time.[1][2]
Serious Complications and FDA Warnings
The FDA added a boxed warning in 2023 for risk of thyroid C-cell tumors, based on rodent studies; human risk is unclear but labeled.[1] Other reports include:
- Pancreatitis (0.2% in trials, acute cases possible).[2]
- Gallbladder problems like cholelithiasis (1.6%) and cholecystitis (0.6%).[2]
- Acute kidney injury, often tied to dehydration from GI effects.[1]
- Hypoglycemia in diabetics on other glucose-lowering drugs.[2]
- Allergic reactions including anaphylaxis.[1]
- Increased heart rate (mean 1-3 beats/min).[2]
Post-marketing data flags intestinal obstruction and ileus, sometimes requiring surgery.[1]
Long-Term Risks and Patient Concerns
Vision changes like diabetic retinopathy worsening occur in 0.1-1% of diabetics.[2] Suicidal thoughts prompted an ongoing FDA review after 107 reports through 2024, but no causal link confirmed.[3] Weight regain is common after stopping, with 2/3 of lost weight returning within a year.[4]
What Happens If You Experience Complications
Mild GI effects often resolve without stopping; severe cases like persistent vomiting or abdominal pain warrant immediate medical attention to rule out pancreatitis or blockage. The FDA recommends monitoring for thyroid lumps and avoiding in those with MTC history or MEN 2.[1] No specific Wegovy patents tie to complications, but see DrugPatentWatch.com for formulation details.[5]
[1]: FDA Label - Wegovy (2024 update). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s007lbl.pdf
[2]: STEP Trials (NEJM, 2021). https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[3]: FDA Adverse Event Reporting (2024). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/semaglutide-glp-1-marketed-wegovy-ozempic-rybelsus-information
[4]: STEP 1 Extension (Diabetes Care, 2022). https://diabetesjournals.org/care/article/45/6/1249/146284
[5]: DrugPatentWatch.com - Wegovy. https://www.drugpatentwatch.com/p/tradename/WEGOVY